The Advent of Omics Sciences in Clinical Trials of Motor Neuron Diseases

Journal of Personalized Medicine

卷:12

Sebastiano Cavallaro¹  Paola Ruffo²  Francesca Luisa Conforti² 

[1] Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 95126 Catania, Italy;

[2] Medical Genetics Laboratory, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy;

关键词: clinical trials;    omics;    personalized medicine;    neurodegenerative disease;    motor neuron disease;    amyotrophic lateral sclerosis;   

DOI  :  10.3390/jpm12050758

来源: DOAJ

【 摘 要 】

The “omics revolution” has totally changed the scientific research approach and is contributing to the development of personalized therapies. In motor neuron diseases (MNDs), a set of complex, multifactorial, late-onset and chronic neurodegenerative diseases, the use of multi-omics approaches in clinical trials is providing new opportunities to stratify patients and develop target therapies. To show how omics science is gaining momentum in MNDs, in this work, we review the interventional clinical trials for MNDs based on the application of omics sciences. We analyze a total of 62 clinical trials listed in the ClinicalTrials database where different omics approaches have been applied in an initial phase, for diagnosis or patient selection, or in subsequent stages to cluster subjects, identify molecular signatures or evaluate drugs security or efficacy. The rise of omics sciences in clinical experimentation of MNDs is leading to an upheaval in their diagnosis and therapy that will require significant investments and means to ensure the correct and rapid evolution of personalized medicine.

【 授权许可】

Unknown